Bavarian Nordic (OTCMKTS:BVNRY) Share Price Passes Below Two Hundred Day Moving Average - Here's Why

Key Points

• Bavarian Nordic (OTCMKTS:BVNRY) crossed below its 200-day moving average of $10.56, trading as low as $9.67 and last at $9.75 on light volume (712 shares), down about 0.2%.
• The company reported quarterly results on March 12 showing a loss of ($0.20) EPS on $226.16 million in revenue, with a 22.2% net margin and 11.44% ROE; analysts expect 0.67 EPS for the current year.
• Bavarian Nordic is a vaccine and immunotherapy maker with approved products such as Jynneos (Imvamune/Imvanex), Rabipur and Encepur, and a market capitalization of $2.32 billion (P/E 11.08).

Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report) crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $10.56 and traded as low as $9.67. Bavarian Nordic shares last traded at $9.75, with a volume of 712 shares changing hands.

Bavarian Nordic Trading Down 0.2%

The firm has a market capitalization of $2.32 billion, a P/E ratio of 11.08 and a beta of 1.34. The company has a 50-day moving average of $9.99 and a 200-day moving average of $10.56.

Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report) last issued its quarterly earnings results on Thursday, March 12th. The company reported ($0.20) earnings per share for the quarter. The company had revenue of $226.16 million during the quarter. Bavarian Nordic had a net margin of 22.20% and a return on equity of 11.44%. Research analysts predict that Bavarian Nordic will post 0.67 EPS for the current year.

Bavarian Nordic Company Profile

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic's operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company's commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.